Demirci, U. Et Al. 2013. Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO). JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.139, no.5 , 829-835.

Demirci, U., Tufan, G., Aktas, B., Balakan, O., ALACACIOĞLU, A., Dane, F., ... ENGİN, H.(2013). Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO). JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.139, no.5, 829-835.

Demirci, Umut Et Al. "Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO)," JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.139, no.5, 829-835, 2013

Demirci, Umut Et Al. "Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO)." JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.139, no.5, pp.829-835, 2013

Demirci, U. Et Al. (2013) . "Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO)." JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.139, no.5, pp.829-835.

@article{article, author={Umut Demirci Et Al. }, title={Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO)}, journal={JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY}, year=2013, pages={829-835} }